CD19 and neoplasm: While CD19-targeting CAR-T cell therapies have demonstrated curative events in B-cell malignancies18,19, efficacy in solid tumors appears to be limited by heterogeneity, lack of relevant tumor-specific or -associated antigens and low immunogenicity20, in balance with other immunosuppressive pathways not addressed within the tumor microenvironment.